Evidence map›Paper›PMID 38769961›Full record

ArticleRSC advances2024

Ion Trap LC/MS reveals the generation of reactive intermediates in acalabrutinib metabolism: phase I metabolic profiling and bioactivation pathways elucidation.

Aishah M Alsibaee, Haya I Aljohar, Mohamed W Attwa, Ali S Abdelhameed, Adnan A Kadi

Abstract read
In one paragraph

Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aishah M AlsibaeeDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University Riyadh Saudi Arabia mzeidan@ksu.edu.sa.
Haya I AljoharDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University Riyadh Saudi Arabia mzeidan@ksu.edu.sa.ORCID https://orcid.org/0000-0001-8873-1040
Mohamed W AttwaDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University Riyadh Saudi Arabia mzeidan@ksu.edu.sa.ORCID https://orcid.org/0000-0002-1147-4960
Ali S AbdelhameedDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University Riyadh Saudi Arabia mzeidan@ksu.edu.sa.ORCID https://orcid.org/0000-0002-5910-2832
Adnan A KadiDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University Riyadh Saudi Arabia mzeidan@ksu.edu.sa.ORCID https://orcid.org/0000-0001-8115-4228

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acalabrutinib (CALQUENCE; ACB) is a Bruton tyrosine kinase inhibitor (BTKI) used to treat mantle cell lymphoma, small lymphocytic lymphoma (SLL), and chronic lymphocytic leukemia (CLL). On 21 November 2019, ACB was approved by the U.S. FDA for the use as a single therapy for the treatment of CLL/SLL.

Identifiers

PMID38769961
PMCPMC11103460

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.